These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26802016)

  • 1. Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium.
    Gaudet MM; Barrdahl M; Lindström S; Travis RC; Auer PL; Buring JE; Chanock SJ; Eliassen AH; Gapstur SM; Giles GG; Gunter M; Haiman C; Hunter DJ; Joshi AD; Kaaks R; Khaw KT; Lee IM; Le Marchand L; Milne RL; Peeters PH; Sund M; Tamimi R; Trichopoulou A; Weiderpass E; Yang XR; Prentice RL; Feigelson HS; Canzian F; Kraft P
    Breast Cancer Res Treat; 2016 Feb; 155(3):531-40. PubMed ID: 26802016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women.
    Wang X; Kapoor PM; Auer PL; Dennis J; Dunning AM; Wang Q; Lush M; Michailidou K; Bolla MK; Aronson KJ; Murphy RA; Brooks-Wilson A; Lee DG; Cordina-Duverger E; Guénel P; Truong T; Mulot C; Teras LR; Patel AV; Dossus L; Kaaks R; Hoppe R; Lo WY; Brüning T; Hamann U; Czene K; Gabrielson M; Hall P; Eriksson M; Jung A; Becher H; Couch FJ; Larson NL; Olson JE; Ruddy KJ; Giles GG; MacInnis RJ; Southey MC; Le Marchand L; Wilkens LR; Haiman CA; Olsson H; Augustinsson A; Krüger U; Wagner P; Scott C; Winham SJ; Vachon CM; Perou CM; Olshan AF; Troester MA; Hunter DJ; Eliassen HA; Tamimi RM; Brantley K; Andrulis IL; Figueroa J; Chanock SJ; Ahearn TU; García-Closas M; Evans GD; Newman WG; van Veen EM; Howell A; Wolk A; Håkansson N; Anton-Culver H; Ziogas A; Jones ME; Orr N; Schoemaker MJ; Swerdlow AJ; Kitahara CM; Linet M; Prentice RL; Easton DF; Milne RL; Kraft P; Chang-Claude J; Lindström S
    Sci Rep; 2022 Apr; 12(1):6199. PubMed ID: 35418701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density.
    Rudolph A; Fasching PA; Behrens S; Eilber U; Bolla MK; Wang Q; Thompson D; Czene K; Brand JS; Li J; Scott C; Pankratz VS; Brandt K; Hallberg E; Olson JE; Lee A; Beckmann MW; Ekici AB; Haeberle L; Maskarinec G; Le Marchand L; Schumacher F; Milne RL; Knight JA; Apicella C; Southey MC; Kapuscinski MK; Hopper JL; Andrulis IL; Giles GG; Haiman CA; Khaw KT; Luben R; Hall P; Pharoah PD; Couch FJ; Easton DF; Dos-Santos-Silva I; Vachon C; Chang-Claude J
    Breast Cancer Res; 2015 Aug; 17(1):110. PubMed ID: 26275715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between current vitamin D supplementation and menopausal hormone therapy use on breast cancer risk: evidence from the E3N cohort.
    Cadeau C; Fournier A; Mesrine S; Clavel-Chapelon F; Fagherazzi G; Boutron-Ruault MC
    Am J Clin Nutr; 2015 Oct; 102(4):966-73. PubMed ID: 26354532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between menopausal hormone therapy, mammographic density and breast cancer risk: results from the E3N cohort study.
    Fornili M; Perduca V; Fournier A; Jérolon A; Boutron-Ruault MC; Maskarinec G; Severi G; Baglietto L
    Breast Cancer Res; 2021 Apr; 23(1):47. PubMed ID: 33865453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A genome-wide association study to identify genetic susceptibility loci that modify ductal and lobular postmenopausal breast cancer risk associated with menopausal hormone therapy use: a two-stage design with replication.
    Hein R; Flesch-Janys D; Dahmen N; Beckmann L; Lindström S; Schoof N; Czene K; Mittelstraß K; Illig T; Seibold P; Behrens S; Humphreys K; Li J; Liu J; Olson JE; Wang X; Hankinson SE; Truong T; Menegaux F; Dos Santos Silva I; Johnson N; ; Chen ST; Yu JC; Ziogas A; Kataja V; Kosma VM; Mannermaa A; Anton-Culver H; Shen CY; Brauch H; Peto J; Guénel P; Kraft P; Couch FJ; Easton DF; Hall P; Chang-Claude J
    Breast Cancer Res Treat; 2013 Apr; 138(2):529-542. PubMed ID: 23423446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphism Thr160Thr in SRD5A1, involved in the progesterone metabolism, modifies postmenopausal breast cancer risk associated with menopausal hormone therapy.
    Hein R; Abbas S; Seibold P; Salazar R; Flesch-Janys D; Chang-Claude J
    Breast Cancer Res Treat; 2012 Jan; 131(2):653-61. PubMed ID: 21947678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association of polymorphisms in hormone metabolism pathway genes, menopausal hormone therapy, and breast cancer risk: a nested case-control study in the California Teachers Study cohort.
    Lee E; Schumacher F; Lewinger JP; Neuhausen SL; Anton-Culver H; Horn-Ross PL; Henderson KD; Ziogas A; Van Den Berg D; Bernstein L; Ursin G
    Breast Cancer Res; 2011 Apr; 13(2):R37. PubMed ID: 21457551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3).
    Dossus L; Kaaks R; Canzian F; Albanes D; Berndt SI; Boeing H; Buring J; Chanock SJ; Clavel-Chapelon F; Feigelson HS; Gaziano JM; Giovannucci E; Gonzalez C; Haiman CA; Hallmans G; Hankinson SE; Hayes RB; Henderson BE; Hoover RN; Hunter DJ; Khaw KT; Kolonel LN; Kraft P; Ma J; Le Marchand L; Lund E; Peeters PH; Stampfer M; Stram DO; Thomas G; Thun MJ; Tjonneland A; Trichopoulos D; Tumino R; Riboli E; Virtamo J; Weinstein SJ; Yeager M; Ziegler RG; Cox DG
    Carcinogenesis; 2010 Mar; 31(3):455-61. PubMed ID: 19965896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium.
    Campa D; Kaaks R; Le Marchand L; Haiman CA; Travis RC; Berg CD; Buring JE; Chanock SJ; Diver WR; Dostal L; Fournier A; Hankinson SE; Henderson BE; Hoover RN; Isaacs C; Johansson M; Kolonel LN; Kraft P; Lee IM; McCarty CA; Overvad K; Panico S; Peeters PH; Riboli E; Sanchez MJ; Schumacher FR; Skeie G; Stram DO; Thun MJ; Trichopoulos D; Zhang S; Ziegler RG; Hunter DJ; Lindström S; Canzian F
    J Natl Cancer Inst; 2011 Aug; 103(16):1252-63. PubMed ID: 21791674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study.
    DeBono NL; Robinson WR; Lund JL; Tse CK; Moorman PG; Olshan AF; Troester MA
    J Womens Health (Larchmt); 2018 Mar; 27(3):377-386. PubMed ID: 28570827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Menopausal Hormone Therapy use and breast cancer risk by receptor subtypes: Results from the New South Wales Cancer Lifestyle and EvaluAtion of Risk (CLEAR) study.
    Salagame U; Banks E; O'Connell DL; Egger S; Canfell K
    PLoS One; 2018; 13(11):e0205034. PubMed ID: 30403669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Menopausal hormone therapy use and breast cancer risk in Australia: Findings from the New South Wales Cancer, Lifestyle and Evaluation of Risk study.
    Salagame U; Banks E; Sitas F; Canfell K
    Int J Cancer; 2016 Apr; 138(8):1905-14. PubMed ID: 26599391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study.
    Rudolph A; Hein R; Lindström S; Beckmann L; Behrens S; Liu J; Aschard H; Bolla MK; Wang J; Truong T; Cordina-Duverger E; Menegaux F; Brüning T; Harth V; ; Severi G; Baglietto L; Southey M; Chanock SJ; Lissowska J; Figueroa JD; Eriksson M; Humpreys K; Darabi H; Olson JE; Stevens KN; Vachon CM; Knight JA; Glendon G; Mulligan AM; Ashworth A; Orr N; Schoemaker M; Webb PM; ; ; Guénel P; Brauch H; Giles G; García-Closas M; Czene K; Chenevix-Trench G; Couch FJ; Andrulis IL; Swerdlow A; Hunter DJ; Flesch-Janys D; Easton DF; Hall P; Nevanlinna H; Kraft P; Chang-Claude J;
    Endocr Relat Cancer; 2013 Dec; 20(6):875-87. PubMed ID: 24080446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium.
    Rudolph A; Song M; Brook MN; Milne RL; Mavaddat N; Michailidou K; Bolla MK; Wang Q; Dennis J; Wilcox AN; Hopper JL; Southey MC; Keeman R; Fasching PA; Beckmann MW; Gago-Dominguez M; Castelao JE; Guénel P; Truong T; Bojesen SE; Flyger H; Brenner H; Arndt V; Brauch H; Brüning T; Mannermaa A; Kosma VM; Lambrechts D; Keupers M; Couch FJ; Vachon C; Giles GG; MacInnis RJ; Figueroa J; Brinton L; Czene K; Brand JS; Gabrielson M; Humphreys K; Cox A; Cross SS; Dunning AM; Orr N; Swerdlow A; Hall P; Pharoah PDP; Schmidt MK; Easton DF; Chatterjee N; Chang-Claude J; García-Closas M
    Int J Epidemiol; 2018 Apr; 47(2):526-536. PubMed ID: 29315403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.
    MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
    Breast Cancer Res Treat; 2010 Apr; 120(3):727-36. PubMed ID: 19672706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postmenopausal breast cancer risk and interactions between body mass index, menopausal hormone therapy use, and vitamin D supplementation: Evidence from the E3N cohort.
    Cadeau C; Fournier A; Mesrine S; Clavel-Chapelon F; Fagherazzi G; Boutron-Ruault MC
    Int J Cancer; 2016 Nov; 139(10):2193-200. PubMed ID: 27451078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between menopausal hormone therapy and mortality after breast cancer The MARIEplus study, a prospective case cohort.
    Obi N; Heinz J; Seibold P; Vrieling A; Rudolph A; Chang-Claude J; Berger J; Flesch-Janys D
    Int J Cancer; 2016 May; 138(9):2098-108. PubMed ID: 26649645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-Wide Interaction Analysis of Genetic Variants With Menopausal Hormone Therapy for Colorectal Cancer Risk.
    Tian Y; Kim AE; Bien SA; Lin Y; Qu C; Harrison TA; Carreras-Torres R; Díez-Obrero V; Dimou N; Drew DA; Hidaka A; Huyghe JR; Jordahl KM; Morrison J; Murphy N; Obón-Santacana M; Ulrich CM; Ose J; Peoples AR; Ruiz-Narvaez EA; Shcherbina A; Stern MC; Su YR; van Duijnhoven FJB; Arndt V; Baurley JW; Berndt SI; Bishop DT; Brenner H; Buchanan DD; Chan AT; Figueiredo JC; Gallinger S; Gruber SB; Harlid S; Hoffmeister M; Jenkins MA; Joshi AD; Keku TO; Larsson SC; Le Marchand L; Li L; Giles GG; Milne RL; Nan H; Nassir R; Ogino S; Budiarto A; Platz EA; Potter JD; Prentice RL; Rennert G; Sakoda LC; Schoen RE; Slattery ML; Thibodeau SN; Van Guelpen B; Visvanathan K; White E; Wolk A; Woods MO; Wu AH; Campbell PT; Casey G; Conti DV; Gunter MJ; Kundaje A; Lewinger JP; Moreno V; Newcomb PA; Pardamean B; Thomas DC; Tsilidis KK; Peters U; Gauderman WJ; Hsu L; Chang-Claude J
    J Natl Cancer Inst; 2022 Aug; 114(8):1135-1148. PubMed ID: 35512400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Menopausal hormone therapy and cancer risk: An overestimated risk?
    Simin J; Tamimi R; Lagergren J; Adami HO; Brusselaers N
    Eur J Cancer; 2017 Oct; 84():60-68. PubMed ID: 28783542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.